Search

Your search keyword '"Scagliotti Giorgio, V"' showing total 836 results

Search Constraints

Start Over You searched for: Author "Scagliotti Giorgio, V" Remove constraint Author: "Scagliotti Giorgio, V"
836 results on '"Scagliotti Giorgio, V"'

Search Results

2. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

3. The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

7. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.

8. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

9. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

12. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

14. Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

15. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

17. Supplementary Figure S4 from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

18. Data from Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade

19. Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

21. Supplementary Figure 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

22. Supplementary Figure 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

23. Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

24. Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

25. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018

26. Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018

27. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

28. Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018

29. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma

30. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

32. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

33. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

37. Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade

38. Supplementary Figure S15 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

39. Supplementary Table S3 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

40. Data from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

41. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

43. Scientific Advances in Thoracic Oncology 2016

48. The IASLC Early Lung Imaging Confederation (ELIC) Open-Source Deep Learning and Quantitative Measurement Initiative

49. Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer

50. Scientific Advances in Lung Cancer 2015

Catalog

Books, media, physical & digital resources